vs
Side-by-side financial comparison of ENERGIZER HOLDINGS, INC. (ENR) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Insulet Corporation is the larger business by last-quarter revenue ($783.7M vs $778.9M, roughly 1.0× ENERGIZER HOLDINGS, INC.). Insulet Corporation runs the higher net margin — 13.0% vs 1.3%, a 11.7% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs -3.0%). ENERGIZER HOLDINGS, INC. produced more free cash flow last quarter ($2.0B vs $48.2M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs 5.4%).
Energizer Holdings, Inc. is an American manufacturer and one of the world's largest manufacturers of batteries, headquartered in Clayton, Missouri. It produces batteries under the Energizer, Ray-O-Vac, Varta, and Eveready brand names and formerly owned several personal care businesses until it separated that side of the business into a new company called Edgewell Personal Care in 2015.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
ENR vs PODD — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $778.9M | $783.7M |
| Net Profit | $10.1M | $101.6M |
| Gross Margin | 33.2% | 72.6% |
| Operating Margin | — | 18.7% |
| Net Margin | 1.3% | 13.0% |
| Revenue YoY | -3.0% | 31.2% |
| Net Profit YoY | -64.3% | 0.9% |
| EPS (diluted) | $0.15 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $778.9M | — | ||
| Q4 25 | $778.9M | $783.7M | ||
| Q3 25 | $832.8M | $706.3M | ||
| Q2 25 | $725.3M | $649.1M | ||
| Q1 25 | $662.9M | $569.0M | ||
| Q4 24 | $731.7M | $597.5M | ||
| Q3 24 | $805.7M | $543.9M | ||
| Q2 24 | $701.4M | $488.5M |
| Q1 26 | $10.1M | — | ||
| Q4 25 | $-3.4M | $101.6M | ||
| Q3 25 | $34.9M | $87.6M | ||
| Q2 25 | $153.5M | $22.5M | ||
| Q1 25 | $28.3M | $35.4M | ||
| Q4 24 | $22.3M | $100.7M | ||
| Q3 24 | $47.6M | $77.5M | ||
| Q2 24 | $-43.8M | $188.6M |
| Q1 26 | 33.2% | — | ||
| Q4 25 | 32.9% | 72.6% | ||
| Q3 25 | 36.6% | 72.2% | ||
| Q2 25 | 55.1% | 69.7% | ||
| Q1 25 | 39.1% | 71.9% | ||
| Q4 24 | 36.8% | 72.1% | ||
| Q3 24 | 38.1% | 69.3% | ||
| Q2 24 | 39.5% | 67.7% |
| Q1 26 | — | — | ||
| Q4 25 | -0.6% | 18.7% | ||
| Q3 25 | 6.4% | 16.7% | ||
| Q2 25 | 22.6% | 18.7% | ||
| Q1 25 | 5.5% | 15.6% | ||
| Q4 24 | 4.1% | 18.3% | ||
| Q3 24 | 7.4% | 16.2% | ||
| Q2 24 | -8.2% | 11.2% |
| Q1 26 | 1.3% | — | ||
| Q4 25 | -0.4% | 13.0% | ||
| Q3 25 | 4.2% | 12.4% | ||
| Q2 25 | 21.2% | 3.5% | ||
| Q1 25 | 4.3% | 6.2% | ||
| Q4 24 | 3.0% | 16.9% | ||
| Q3 24 | 5.9% | 14.2% | ||
| Q2 24 | -6.2% | 38.6% |
| Q1 26 | $0.15 | — | ||
| Q4 25 | — | $1.42 | ||
| Q3 25 | — | $1.24 | ||
| Q2 25 | — | $0.32 | ||
| Q1 25 | — | $0.50 | ||
| Q4 24 | — | $1.38 | ||
| Q3 24 | — | $1.08 | ||
| Q2 24 | — | $2.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.5M | — |
| Total DebtLower is stronger | $3.3B | $930.8M |
| Stockholders' EquityBook value | $173.2M | $1.5B |
| Total Assets | $4.4B | $3.2B |
| Debt / EquityLower = less leverage | 19.13× | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $172.5M | — | ||
| Q4 25 | $214.8M | — | ||
| Q3 25 | $236.2M | — | ||
| Q2 25 | $171.1M | — | ||
| Q1 25 | $139.3M | — | ||
| Q4 24 | $195.9M | — | ||
| Q3 24 | $216.9M | — | ||
| Q2 24 | $146.7M | — |
| Q1 26 | $3.3B | — | ||
| Q4 25 | — | $930.8M | ||
| Q3 25 | $3.4B | $934.9M | ||
| Q2 25 | $3.2B | $939.0M | ||
| Q1 25 | $3.2B | $1.6B | ||
| Q4 24 | $3.1B | $1.3B | ||
| Q3 24 | $3.2B | $1.4B | ||
| Q2 24 | $3.2B | $1.4B |
| Q1 26 | $173.2M | — | ||
| Q4 25 | $141.3M | $1.5B | ||
| Q3 25 | $169.9M | $1.4B | ||
| Q2 25 | $183.2M | $1.5B | ||
| Q1 25 | $133.9M | $1.3B | ||
| Q4 24 | $140.6M | $1.2B | ||
| Q3 24 | $135.8M | $1.1B | ||
| Q2 24 | $123.4M | $998.4M |
| Q1 26 | $4.4B | — | ||
| Q4 25 | $4.4B | $3.2B | ||
| Q3 25 | $4.6B | $3.0B | ||
| Q2 25 | $4.5B | $3.5B | ||
| Q1 25 | $4.2B | $3.5B | ||
| Q4 24 | $4.2B | $3.1B | ||
| Q3 24 | $4.3B | $3.0B | ||
| Q2 24 | $4.2B | $2.9B |
| Q1 26 | 19.13× | — | ||
| Q4 25 | — | 0.61× | ||
| Q3 25 | 20.28× | 0.68× | ||
| Q2 25 | 17.57× | 0.64× | ||
| Q1 25 | 23.56× | 1.21× | ||
| Q4 24 | 22.17× | 1.07× | ||
| Q3 24 | 23.51× | 1.21× | ||
| Q2 24 | 26.04× | 1.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $183.3M |
| Free Cash FlowOCF − Capex | $2.0B | $48.2M |
| FCF MarginFCF / Revenue | 260.1% | 6.2% |
| Capex IntensityCapex / Revenue | 5.5% | 17.2% |
| Cash ConversionOCF / Net Profit | — | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | $2.2B | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $149.5M | $183.3M | ||
| Q3 25 | $61.5M | $125.7M | ||
| Q2 25 | $21.4M | $196.5M | ||
| Q1 25 | $-12.8M | $63.8M | ||
| Q4 24 | $77.0M | $147.7M | ||
| Q3 24 | $168.9M | $98.5M | ||
| Q2 24 | $45.8M | $96.5M |
| Q1 26 | $2.0B | — | ||
| Q4 25 | $124.2M | $48.2M | ||
| Q3 25 | $46.7M | $100.1M | ||
| Q2 25 | $7.9M | $177.9M | ||
| Q1 25 | $-33.8M | $51.5M | ||
| Q4 24 | $42.4M | $94.1M | ||
| Q3 24 | $141.5M | $71.8M | ||
| Q2 24 | $27.3M | $74.0M |
| Q1 26 | 260.1% | — | ||
| Q4 25 | 15.9% | 6.2% | ||
| Q3 25 | 5.6% | 14.2% | ||
| Q2 25 | 1.1% | 27.4% | ||
| Q1 25 | -5.1% | 9.1% | ||
| Q4 24 | 5.8% | 15.7% | ||
| Q3 24 | 17.6% | 13.2% | ||
| Q2 24 | 3.9% | 15.1% |
| Q1 26 | 5.5% | — | ||
| Q4 25 | 3.2% | 17.2% | ||
| Q3 25 | 1.8% | 3.6% | ||
| Q2 25 | 1.9% | 2.9% | ||
| Q1 25 | 3.2% | 2.2% | ||
| Q4 24 | 4.7% | 9.0% | ||
| Q3 24 | 3.4% | 4.9% | ||
| Q2 24 | 2.6% | 4.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.80× | ||
| Q3 25 | 1.76× | 1.43× | ||
| Q2 25 | 0.14× | 8.73× | ||
| Q1 25 | -0.45× | 1.80× | ||
| Q4 24 | 3.45× | 1.47× | ||
| Q3 24 | 3.55× | 1.27× | ||
| Q2 24 | — | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ENR
Segment breakdown not available.
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
